SynVivo Appoints Dr. Richard Eglen To Its Board Of Directors To Strengthen Scientific Leadership

SynVivo, a leading company in the organ-on-chip space, has announced the appointment of Dr. Richard Eglen as a non-executive member of its Board of Directors. Dr. Eglen brings more than four decades of leadership experience in the life sciences sector, having held prominent roles at companies such as Corning, PerkinElmer (now Revvity), DiscoverX (now part of Eurofins), and Roche. In addition to his corporate roles, he has served as a senior advisor to Arsenal Capital Partners and continues to serve on the boards of several notable organizations in the life sciences industry.

SynVivo is focused on transforming biomedical research and drug development through the creation of advanced microfluidic platforms that replicate the intricate microenvironments of human tissues. These in vitro models are designed to closely mimic human biology, offering a more accurate and predictive alternative to traditional testing methods. This approach is especially timely in light of recent developments such as the FDA’s Modernization Act, which encourages the adoption of innovative, human-relevant technologies to enhance drug safety and efficacy evaluations.

Gwen Fewell, PhD, President and CEO of SynVivo, said in a statement, “We are excited to welcome Dr. Eglen to SynVivo’s Board. His vast experience and insight will strengthen our leadership team as we scale our offerings to address critical gaps in drug development with more predictive and human-relevant platforms.”

Dr. Eglen stated, “I am delighted to join SynVivo at this pivotal time. I look forward to supporting the company’s mission to advance innovative technologies that improve drug discovery outcomes and align with regulatory priorities aimed at modernizing preclinical testing.”

With the addition of Dr. Eglen to the board, SynVivo strengthens its leadership team at a pivotal moment in its growth. His extensive experience and strategic insight are expected to play a key role in supporting the company’s mission to expand the use of organ-on-chip technologies across drug discovery, development, and translational research. His guidance will also help SynVivo deliver scalable and reproducible solutions to its expanding base of biotech, pharmaceutical, and academic collaborators around the world.